Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

Exclusion Criteria

• •Vegetarians
• •Positive to H. pylori by 13C urea breath test or stool antigen test at screening visit
• •Contra-indication to proton pump inhibitors treatment
• •Previous participation in a trial with PPIs within 3 months
• •Current or historical evidence of clinically relevant cardiovascular, neurological, hematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolic or psychiatric disease
• •Any other acute or chronic disease which could influence the volunteer's health and/or the study results
• •Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or hernia repair
• •Receipt of medication (including 'over the counter' preparations) within two weeks of dosing
• •Use of enzyme inducers or enzyme inhibitor drugs within the last three months before the first drug administration
• •Participation in a clinical trial involving receipt of a licensed (marketed) medicinal product or of an unlicensed (investigational) medicinal product within one month before the study
• •Past or current drug exposure amounting to drug abuse or addiction
• •Past or current alcohol exposure amounting to alcohol abuse or addiction; (i.e. \> 28 units per week for males, where 1 unit = one measure of spirit (25 mL), one glass of wine (125 mL) or ½ pint beer)
• •Currently smoke \>10 cigarettes per day
• •Donation of blood or any other major blood loss (\>500 mL) within three months before the study
• •Unwilling or unable to comply with the study protocol for any reason or in the opinion of the investigator should not participate in the study
• •Positive test for hepatitis B surface antigen, hepatitis C antibody, HIV1 or HIV2 antibody at screening
• •Known allergy or intolerance to lactose
• •Known allergy or intolerance to any other compound in the study drug or any other closely related compound